CALCA and Cerebral ischemia: Of special note is the potential therapeutic dilemma as, on the one hand, it is highly conceivable that the psycho- and vasoactive neuropeptide CGRP is—at least in part—involved in the pathogenesis of reduced hrQoL after good-grade sSAH, whereas on the other hand, CGRP was certified a cerebroprotective role by counteracting sSAH-induced vasoconstriction and CV-related cerebral ischemia.